Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban?

Transfusion and Apheresis Science

Volumn 55, Issue 2, 2016, Pages 212-215

  Yates, Sean G ^a   Smith, Sabra ^a   Tharpe, William ^a   Shen, Yu Min ^a   Sarode, Ravi ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Anti Xa; Direct oral anticoagulants; Laboratory; Low molecular weight heparin; Rivaroxaban

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; BLOOD CLOTTING FACTOR 10A;

ANTI XA ASSAY; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; ASSAY; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EVALUATION; DOSE RESPONSE; DRUG BLOOD LEVEL; EX VIVO STUDY; HUMAN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RETROSPECTIVE STUDY; BLOOD CLOTTING TEST; EVALUATION STUDY; FEMALE; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; BLOOD COAGULATION TESTS; FACTOR XA; FACTOR XA INHIBITORS; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; RIVAROXABAN;

EID: 84992390120     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2016.06.005     Document Type: Article

References (14)

1. [1] Samama, M.M., The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants. Thromb Res 127 (2011), 497–504.
2. [2] Halabi, A., Kubitza, D., Zuehlsdorf, M., Becka, M., Mueck, W., Maatouk, H., Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban – an oral, direct Factor Xa inhibitor. J Thromb Haemost 5 (2007), PM–635.
3. [3] Nutescu, E., Chuatrisorn, I., Hellenbart, E., Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 31 (2011), 326–343.
4. [4] Harder, S., Parisius, J., Picard-Willems, B., Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications. Thromb Res 123 (2008), 396–403.
5. [5] Barrett, Y.C., Wang, Z., Frost, C., Shenker, A., Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 104 (2010), 1263–1271.
6. [6] Samama, M.M., Martinoli, J.-L., LeFlem, L., Guinet, C., Plu-Bureau, G., Depasse, F., et al. Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor. Thromb Haemost 103 (2010), 815–825.
7. [7] Hillarp, A., Baghaei, F., Fagerberg Blixter, I., Gustafsson, K.M., Stigendal, L., Sten-Linder, M., et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 9 (2011), 133–139.
8. [8] Mueck, W., Lensing, A.W.A., Agnelli, G., Decousus, H., Prandoni, P., Misselwitz, F., Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 50 (2011), 675–686.
9. [9] Samama, M.M., Contant, G., Spiro, T.E., Perzborn, E., Guinet, C., Gourmelin, Y., et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 107 (2012), 379–387.
10. [10] Lindhoff-Last, E., Ansell, J., Spiro, T., Samama, M.M., Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays. Ann Med 45 (2013), 423–429.
11. [11] Hawes, E.M., Deal, A.M., Funk-Adcock, D., Gosselin, R., Jeanneret, C., Cook, A.M., et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 11 (2013), 1493–1502.
12. [12] Francart, S.J., Hawes, E.M., Deal, A.M., Adcock, D.M., Gosselin, R., Jeanneret, C., et al. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. Thromb Haemost 111 (2014), 1133–1140.
13. [13] Veen, J., Smith, J., van Veen, J.J., Kitchen, S., Makris, M., Smith, J., et al. Normal prothrombin time in the presence of therapeutic levels of rivaroxaban. Br J Haematol 160 (2013), 859–861.
14. [14] Siegal, D.M., Curnutte, J.T., Connolly, S.J., Lu, G., Conley, P.B., Wiens, B.L., et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373 (2015), 2413–2424.